0000899243-23-004208.txt : 20230207 0000899243-23-004208.hdr.sgml : 20230207 20230207174603 ACCESSION NUMBER: 0000899243-23-004208 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230203 FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henn Matthew R. CENTRAL INDEX KEY: 0001767321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 23596324 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-03 0 0001609809 Seres Therapeutics, Inc. MCRB 0001767321 Henn Matthew R. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Restricted Stock Units 2023-02-03 4 A 0 45000 0.00 A Common Stock 45000 45000 D Stock Option (Right to Buy) 5.50 2023-02-03 4 A 0 90000 0.00 A 2033-02-02 Common Stock 90000 90000 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Chief Scientific Officer and EVP /s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn 2023-02-07